$BEAM earnings report

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio. AlphAI read Beam Therapeutics's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readBEAM · Third Quarter 2026 · ended September 30, 2026

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio

→Mixed quarter

Clinical and regulatory milestones advanced across risto-cel, BEAM-302 and BEAM-301, while quarterly license and collaboration revenue was $ 307 and net loss widened to $ (134,405 ) from $ (112,571 ).

Revenue
$307K

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
License and collaboration revenue, three months ended September 30GAAP$307K––
Research and development expense, three months ended September 30GAAP110,110––
General and administrative expense, three months ended September 30GAAP31,519––
Total operating expenses, three months ended September 30GAAP141,629––
Loss from operations, three months ended September 30GAAP(141,322 )––
Change in fair value of derivative liabilities, three months ended September 30GAAP4,700––
Change in fair value of non-controlling equity investments, three months ended September 30GAAP(1,021 )––
Change in fair value of contingent consideration liabilities, three months ended September 30GAAP(2,856 )––
Gain on sale of equity method investment, three months ended September 30GAAP—––
Interest and other income (expense), net, three months ended September 30GAAP6,094––
Total other income (expense), three months ended September 30GAAP6,917––
Net loss, three months ended September 30GAAP−$134.4M––
Unrealized gain (loss) on marketable securities, three months ended September 30GAAP(1,245 )––
Comprehensive loss, three months ended September 30GAAP−$135.7M––
Net loss per common share, basic and diluted, three months ended September 30GAAP$ (1.28 )––
Weighted-average common shares outstanding, basic and diluted, three months ended September 30GAAP104,698,517––
License and collaboration revenue, nine months ended September 30GAAP$32.53M––
Research and development expense, nine months ended September 30GAAP309,730––
General and administrative expense, nine months ended September 30GAAP97,895––
Total operating expenses, nine months ended September 30GAAP407,625––
Loss from operations, nine months ended September 30GAAP(375,090 )––
Change in fair value of derivative liabilities, nine months ended September 30GAAP3,000––
Change in fair value of non-controlling equity investments, nine months ended September 30GAAP(667 )––
Change in fair value of contingent consideration liabilities, nine months ended September 30GAAP(2,547 )––
Gain on sale of equity method investment, nine months ended September 30GAAP455––
Interest and other income (expense), net, nine months ended September 30GAAP23,448––
Total other income (expense), nine months ended September 30GAAP23,689––
Net loss, nine months ended September 30GAAP−$351.4M––
Unrealized gain (loss) on marketable securities, nine months ended September 30GAAP(4,545 )––
Comprehensive loss, nine months ended September 30GAAP−$355.9M––
Net loss per common share, basic and diluted, nine months ended September 30GAAP$ (3.38 )––
Weighted-average common shares outstanding, basic and diluted, nine months ended September 30GAAP104,100,991––
Cash, cash equivalents, and marketable securitiesGAAP$1.04B––
Total assetsGAAP1,269,072––
Total liabilitiesGAAP316,398––
Total stockholders’ equityGAAP952,674––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Into mid-2029 outlook

  • NoteCash runway expected to support operating plans into mid-2029.
  • NoteAn additional $200 million is expected to be drawn from the company’s facility with Sixth Street, assuming satisfaction of the conditions applicable to those additional borrowings.
  • NoteCompletion of dosing in the BEAM-302 global pivotal cohort is expected in the first half of 2027.
  • NoteU.S. BLA submission for risto-cel in sickle cell disease is expected as early as year-end 2026.
  • NoteUpdated risto-cel clinical data are expected by year-end 2026.
  • NoteDosing in the Phase 1/2 trial of BEAM-304 is expected to initiate in early 2027.

What drove it

  • Updated BEAM-302 Phase 1/2 data presented at ERS demonstrated durable increases in functional AAT and reductions in mutant Z-AAT, with up to 18 months of follow-up.
  • Initial BEAM-301 Phase 1/2 data demonstrated dose-dependent improvements in time to fasting hypoglycemia across all patients.
  • Two of three patients in the 40 mg BEAM-301 cohort achieved the protocol-defined maximum controlled fasting duration of ≥15 hours, with complete elimination of starch supplementation.
  • Beam is enrolling patients in the 60 mg cohort of the BEAM-301 open-label Phase 1/2 dose-exploration study.
  • Beam nominated its third base editor within the BEAM-304 program, which the company believes has the potential to address up to 50% of PKU patients in the U.S.
  • Targeted LNPs for HSC delivery have been identified and are in advanced lead optimization.

Concerns

  • License and collaboration revenue was $ 307 for the third quarter of 2026, compared to $ 9,698 for the third quarter of 2025.
  • Net loss was $ (134,405 ) for the third quarter of 2026, compared to $ (112,571 ) for the third quarter of 2025.
  • General and administrative expense was 31,519 for the third quarter of 2026, compared to 26,740 for the third quarter of 2025.
  • Cash, cash equivalents, and marketable securities were $ 1,043,873 as of September 30, 2026, compared to $ 1,245,210 as of December 31, 2025.
  • The expected additional $200 million borrowing from Sixth Street is subject to satisfaction of conditions applicable to those borrowings.
  • BEAM-302, BEAM-304, BEAM-301 and risto-cel remain investigational programs.

What to watch

  • Updated risto-cel clinical data expected by year-end 2026 and the potential U.S. BLA submission as early as year-end 2026.
  • Completion of dosing in the BEAM-302 global pivotal cohort expected in the first half of 2027.
  • Initiation of BEAM-304 Phase 1/2 dosing expected in early 2027.
  • Enrollment and findings from the 60 mg BEAM-301 cohort and planned engagement with the U.S. FDA regarding a potential path to approval.
  • Satisfaction of conditions applicable to the expected additional $200 million draw from the Sixth Street facility.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025.
  • Cash, cash equivalents, and marketable securities were $ 1,043,873 as of September 30, 2026, compared to $ 1,245,210 as of December 31, 2025.
  • Total assets were 1,269,072 as of September 30, 2026, compared to 1,481,177 as of December 31, 2025.
  • Total liabilities were 316,398 as of September 30, 2026, compared to 242,819 as of December 31, 2025.
  • Total stockholders’ equity was 952,674 as of September 30, 2026, compared to 1,238,358 as of December 31, 2025.

Analysis

Beam reported $ 307 of license and collaboration revenue for the third quarter of 2026, versus $ 9,698 in the third quarter of 2025. Research and development expense was 110,110 versus 109,769, while general and administrative expense was 31,519 versus 26,740. Total operating expenses were 141,629, and loss from operations was (141,322 ). Net loss was $ (134,405 ), or $ (1.28 ) per common share, compared with $ (112,571 ), or $ (1.10 ) per common share.

For the nine months ended September 30, license and collaboration revenue was $ 32,535, compared with $ 25,634 in the prior-year period. Research and development expense was 309,730 compared with 310,343, while general and administrative expense was 97,895 compared with 81,539. Nine-month net loss was $ (351,401 ), or $ (3.38 ) per common share, compared with $ (323,039 ), or $ (3.31 ) per common share.

The operational update centered on advancing clinical programs. BEAM-302 Phase 1/2 data presented at ERS showed durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers following a single dose, with up to 18 months of follow-up. Initial BEAM-301 data showed dose-dependent improvements in time to fasting hypoglycemia across all patients, and two of three patients in the 40 mg cohort achieved a controlled fasting duration of ≥15 hours with complete elimination of starch supplementation.

The near-term development calendar includes updated risto-cel data by year-end 2026 and a potential U.S. BLA submission as early as year-end 2026. Beam expects to complete dosing in the BEAM-302 pivotal cohort in the first half of 2027 and initiate BEAM-304 Phase 1/2 dosing in early 2027. The company ended September 30, 2026 with $ 1,043,873 of cash, cash equivalents, and marketable securities and expects its capital resources, together with an additional $200 million expected from its Sixth Street facility subject to applicable conditions, to fund anticipated operating expenses and capital expenditure requirements into mid-2029.

Management, verbatim

Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach.

John Evans, chief executive officer of Beam Therapeutics

We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027.

John Evans, chief executive officer of Beam Therapeutics

Not in the filing

stated, not guessed
  • Total revenue line item separate from license and collaboration revenue
  • Financial segment revenue and segment profitability
  • Gross profit and gross margin
  • Non-GAAP financial measures
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt balance and debt maturity details
  • Share repurchases
  • Dividends
  • Forward revenue guidance
  • Forward gross margin guidance
  • Forward operating expense guidance
  • Forward tax-rate guidance
  • Prior-quarter comparisons for reported financial metrics
  • Explicit year-over-year percentage changes for reported financial metrics
  • The previous outlook covered 2026 and later periods and did not give quarterly guidance for the third quarter, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readBEAM · second quarter of 2026 · ended June 30, 2026

Beam Therapeutics reported second quarter 2026 results, dosed the first patient in the BEAM-302 global pivotal cohort, and completed dosing in the adult and adolescent BEACON trial population for risto-cel.

→Mixed quarter

Clinical and regulatory execution advanced across BEAM-302, risto-cel and BEAM-304, while net loss was $122.7 million versus $102.1 million in the second quarter of 2025 and the balance-sheet table reported cash, cash equivalents, and marketable securities of $1,152,927 as of June 30, 2026.

EPS · other
$1.18

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Cash, cash equivalents and marketable securitiesother$1.2B––
Research & Development (R&D) Expensesother$95.1M––
General & Administrative (G&A) Expensesother$31.9M––
Net lossother$122.7M––
Net loss per shareother$1.18 per share––
Cash, cash equivalents, and marketable securitiesother$1.15B––
Total assetsother1,386,355––
Total liabilitiesother318,913––
Total stockholders’ equityother1,067,442––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 and into mid-2029 outlook

  • NoteCash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029.
  • NoteBeam expects to report initial clinical data for BEAM-301 in 2026.
  • NoteBeam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026.
  • NoteDetailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026.

What drove it

  • Beam dosed the first patient in the global pivotal cohort of the Phase 1/2 BEAM-302 trial in July.
  • Dosing is complete in all adult and adolescent patients enrolled in the Phase 1/2 BEACON trial of risto-cel.
  • The U.S. Food and Drug Administration cleared the investigational new drug application for BEAM-304 in June, and Beam initiated clinical start-up activities for the planned Phase 1/2 trial.
  • Beam completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103; treatment was well tolerated across all doses tested.

Concerns

  • Net loss was $122.7 million, or $1.18 per share, compared to net loss of $102.1 million, or $1.00 per share, for the second quarter of 2025.
  • G&A expenses were $31.9 million, compared to $26.9 million for the second quarter of 2025.
  • The cash-runway expectation includes an additional $200 million expected to be drawn from the company’s facility with Sixth Street.
  • The BLA submission for risto-cel is expected as early as year-end 2026, and the BEAM-302 cohort is designed to support a potential accelerated approval path rather than representing an approval.

What to watch

  • Detailed and updated BEAM-302 clinical data at the ERS Congress, taking place September 5-9, 2026.
  • Rapid enrollment in the BEAM-302 pivotal cohort.
  • Initial clinical data for BEAM-301 in 2026.
  • Updated BEACON trial data by year-end 2026.
  • Potential BLA submission for risto-cel as early as year-end 2026.
  • Clinical start-up and planned Phase 1/2 execution for BEAM-304.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities were $1.2 billion as of June 30, 2026, compared to $1.2 billion as of December 31, 2025.
  • Cash, cash equivalents, and marketable securities were $ 1,152,927 as of June 30, 2026, compared to $ 1,245,210 as of December 31, 2025.
  • Total assets were 1,386,355 as of June 30, 2026, compared to 1,481,177 as of December 31, 2025.
  • Total liabilities were 318,913 as of June 30, 2026, compared to 242,819 as of December 31, 2025.
  • Total stockholders’ equity was 1,067,442 as of June 30, 2026.
  • An additional $200 million is expected to be drawn from the company’s facility with Sixth Street.

Analysis

Beam’s reported quarter was defined by pipeline execution rather than commercial financial performance. The company dosed the first patient in the global pivotal cohort for BEAM-302 in July, completed dosing of adult and adolescent patients in the Phase 1/2 BEACON trial of risto-cel, and received FDA clearance of the IND for BEAM-304 in June. The BEAM-302 cohort is intended to support a potential accelerated approval path in the United States, while BEAM-304 has entered clinical start-up activities for its planned Phase 1/2 trial.

Expense and loss data show continued investment in development programs. R&D expenses were $95.1 million for the second quarter of 2026, compared with $101.8 million for the second quarter of 2025. G&A expenses were $31.9 million, compared with $26.9 million. Net loss was $122.7 million, or $1.18 per share, compared with net loss of $102.1 million, or $1.00 per share, in the prior-year quarter.

Liquidity remains the central financial support for the clinical plan. The press release stated cash, cash equivalents and marketable securities of $1.2 billion as of June 30, 2026, compared with $1.2 billion as of December 31, 2025. The condensed consolidated balance-sheet table reported cash, cash equivalents, and marketable securities of $ 1,152,927 at June 30, 2026, versus $ 1,245,210 at December 31, 2025, with total liabilities of 318,913 at June 30, 2026. Management expects available cash together with an additional $200 million expected to be drawn from the Sixth Street facility to fund operating expenses and capital expenditure requirements into mid-2029.

The upcoming catalyst sequence is concentrated in clinical data and regulatory activity. Updated BEAM-302 data are scheduled for the ERS Congress on September 5-9, 2026. Beam also expects initial BEAM-301 clinical data in 2026, updated BEACON data by year-end 2026, and a risto-cel BLA submission as early as year-end 2026. Execution against these events, including enrollment of the BEAM-302 pivotal cohort and the use of the Sixth Street facility, is central to the stated operating plan.

Management, verbatim

The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam.

John Evans, chief executive officer of Beam Therapeutics

Not in the filing

stated, not guessed
  • Total revenue
  • Revenue prior-year comparison
  • Revenue prior-quarter comparison
  • Revenue growth
  • Segment revenue and segment comparisons
  • Gross profit
  • Gross margin
  • Operating income or loss
  • Operating margin
  • Non-GAAP financial measures
  • Income tax expense or benefit
  • Tax rate
  • Diluted weighted-average shares
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Debt balance
  • Share repurchases
  • Dividends
  • Prior-period outlook for guidance comparison
  • Explicit financial guidance for revenue, gross margin, operating expenses, or tax rate
  • Total stockholders’ equity as of December 31, 2025

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BEAM earnings dates

When is Beam Therapeutics's next earnings date?
AlphAI has no date for BEAM yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.